Uni-Bio Science Group Ltd 2024 SR
The report highlights Uni-Bio Science Group's 2024 performance in the biopharmaceutical sector, specifically in endocrinology, dermatology, and ophthalmology. Key achievements include the successful launch of the osteoporosis product Bogutai and the medical aesthetic product Ji Yantai. The Group conducted a materiality assessment involving stakeholders and identified 11 high-priority ESG issues. Environmental efforts focused on managing emissions and resource use, with a target to maintain discharge intensities over the next 3-5 years. Socially, the Group maintained a zero-fatality record and provided training to 100% of its 487 employees.
Company: Uni-Bio Science Group Ltd
Sector: Health Care
Country: Hong Kong
Year: 2024
Type: SR
Pages: 37
Uni-Bio Science Group Ltd
ESG Report
The report highlights Uni-Bio Science Group's 2024 performance in the biopharmaceutical sector, specifically in endocrinology, dermatology, and ophthalmology. Key achievements include the successful launch of the osteoporosis product Bogutai and the medical aesthetic product Ji Yantai. The Group conducted a materiality assessment involving stakeholders and identified 11 high-priority ESG issues. Environmental efforts focused on managing emissions and resource use, with a target to maintain discharge intensities over the next 3-5 years. Socially, the Group maintained a zero-fatality record and provided training to 100% of its 487 employees.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees